De novo antibody design with experimental success rates that require testing only tens of candidates! Such an inspiring success from the incredibly hardworking Germinal team— huge congrats!
The ability to design antibodies against any protein of interest has major implications for medicine, biotech, and basic science.
Today, we introduce Germinal, a pipeline for epitope-targeted de novo antibody design achieving 4–22% success rates with efficient experimental validation.